First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK) and split kinase family receptors, has demonstrated preclinical anti-tumor activity and modulation of tumor microenvironment. This first-in-human phase 1/1b study included sitravatinib d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Todd, Cho, Byong Chul, Heist, Rebecca, Bazhenova, Lyudmila, Werner, Theresa, Goel, Sanjay, Kim, Dong-Wan, Adkins, Douglas, Carvajal, Richard D., Alva, Ajjai, Eaton, Keith, Wang, Judy, Liu, Yong, Yan, Xiaohong, Christensen, Jamie, Neuteboom, Saskia, Chao, Richard, Pant, Shubham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395446/
https://www.ncbi.nlm.nih.gov/pubmed/35767205
http://dx.doi.org/10.1007/s10637-022-01274-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395446/
https://www.ncbi.nlm.nih.gov/pubmed/35767205
http://dx.doi.org/10.1007/s10637-022-01274-y

Ejemplares similares